Objective: In the present study, we evaluated the effects of the aqueous extract of Physalis angulata root (AEPa) on Leishmania infantum proliferation, morphology, and the driving mechanism in leishmanicidal activity and modulatory action on macrophages.
Methods: L. infantum promastigotes were treated with 50 and 100 µg/mL AEPa for 72 h and then antipromastigote assay was performed by counts in a Newbauer chamber, morphological changes were analyzed by transmission electron microscopy and the mechanism of the leishmanicidal activity was detected. In addition, macrophages were infected with L. infantum and were used to evaluate anti-amastigote activity of AEPa and effects of AEPa on cytokine secretion after 72-hour treatment.
Results: Treatment with AEPa reduced the numbers of L. infantum promastigotes (50% inhibitory concentration (IC) = 65.9 μg/mL; selectivity index (SI) = 22.1) and amastigotes (IC = 37.9 μg/mL; SI = 38.5) compared with the untreated control. Amphotericin B reduced 100% of the promastigote numbers after 72 h of treatment (IC = 0.2 μg/mL). AEPa induced several morphological changes and increased the production of reactive oxygen species and apoptotic death in promastigotes after treating for 72 h. AEPa (100 μg/mL) promoted tumor necrosis factor-α secretion in macrophages infected with L. infantum after 72 h of treatment, but did not induce an increase in this cytokine in noninfected macrophages. In addition, AEPa showed no cytotoxic effect on J774-A1 cells (50% cytotoxic concentration >1000 μg/mL).
Conclusion: AEPa presented antileishmanial activity against the promastigotes and amastigotes of L. infantum without macrophage cytotoxicity; these results show that natural products such as P. angulata have leishmanicidal potential and in the future may be an alternative treatment for leishmaniasis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.joim.2018.08.004 | DOI Listing |
iScience
December 2024
Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, the Netherlands.
Vγ9Vδ2 T cells constitute a homogeneous effector T cell population that lyses tumors of different origin, including the prostate. We generated a bispecific T cell engager (bsTCE) to direct Vγ9Vδ2 T cells to PSMA prostate cancer (PCa) cells. The PSMA-Vδ2 bsTCE triggered healthy donor and PCa patient-derived Vγ9Vδ2 T cells to lyse PSMA PCa cell lines and patient-derived tumor cells while sparing normal prostate cells and enhanced Vγ9Vδ2 T cell antigen cross-presentation to CD8 T cells.
View Article and Find Full Text PDFPolymers (Basel)
June 2024
Material Science and Technology of Materials Department, Kazan State Power Engineering University, 51 Krasnoselskaya str., Kazan 420066, Russia.
Based on organophosphorus branched polyols (AEPAs) synthesized using triethanolamine (TEOA), -phosphoric acid (OPA), and polyoxyethylene glycol with MW = 400 (PEG), vapor-permeable polyurethane ionomers (AEPA-PEG-PUs) were obtained. During the synthesis of AEPAs, the reaction of the OPA etherification with polyoxyethylene glycol was studied in a wide temperature range and at different molar ratios of the starting components. It turned out that OPA simultaneously undergoes a catalytically activated etherification reaction with triethanolamine and PEG.
View Article and Find Full Text PDFSmall
June 2024
State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, China.
Manganese dioxide (MnO) is an attractive cathode material for aqueous zinc batteries (AZBs) owing to its environmental benignity, low cost, high operating voltage, and high theoretical capacity. However, the severe dissolution of Mn leads to rapid capacity decay. Herein, a self-assembled layer of amino-propyl phosphonic acid (AEPA) on the MnO surface, which significantly improves its cycle performance is successfully modified.
View Article and Find Full Text PDFCell Rep Med
March 2023
Amsterdam UMC location Vrije University Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands; LAVA Therapeutics, Utrecht, the Netherlands. Electronic address:
Bispecific T cell engagers (bsTCEs) hold great promise for cancer treatment but face challenges due to the induction of cytokine release syndrome (CRS), on-target off-tumor toxicity, and the engagement of immunosuppressive regulatory T cells that limit efficacy. The development of Vγ9Vδ2-T cell engagers may overcome these challenges by combining high therapeutic efficacy with limited toxicity. By linking a CD1d-specific single-domain antibody (VHH) to a Vδ2-TCR-specific VHH, we create a bsTCE with trispecific properties, which engages not only Vγ9Vδ2-T cells but also type 1 NKT cells to CD1d tumors and triggers robust proinflammatory cytokine production, effector cell expansion, and target cell lysis in vitro.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!